Heart disease is the leading cause of death in women in the UK, killing twice as many women as breast cancer. Yet most people still imagine a heart attack as a man clutching his chest with pain shooting down his arm. According to NHS doctor Dr. Punam Krishan, this outdated image is misleading and dangerous because the signs in women are often very different and frequently missed.

“Heart disease is the number one killer of women in the UK,” Dr. Krishan explains in an Instagram video. “It kills twice as many women as breast cancer, yet awareness is shockingly low.” The problem lies in what she calls diagnostic bias. Medical training, textbooks, and messaging have historically focused on male symptoms, leaving women out of the picture. This leads to missed or misdiagnosed heart attacks in women.

When Chest Pain Isn’t the Main Sign

Women often do not get the “classic” heart attack signs we have all been taught to look for. Instead, their symptoms can be silent, subtle, and easily dismissed as something less serious.

“Women might experience chest tightness or pressure rather than outright pain,” Dr. Krishan says. “Other signs include sudden extreme tiredness, shortness of breath, nausea or vomiting, jaw or neck pain, pain in the shoulders or upper back, dizziness, lightheadedness, cold sweats, or even just a gut feeling that something is not right.”

That gut feeling, she insists, should never be ignored. “Over my 20 years as a doctor, I have seen too many women brush off these symptoms or worse, not be taken seriously when they speak up.”

Why Women’s Symptoms Go Under the Radar

Heart attacks in women are not just missed by doctors; they are often missed by women themselves. The tendency to downplay symptoms or chalk them up to stress, fatigue, or “probably nothing” is common. Dr. Krishan stresses that this cultural and personal dismissal is a huge risk.

There is this habit of minimising what is happening in our bodies. “But one sentence—‘I’m worried this could be my heart’—could make all the difference.”

This is where advocacy comes in. Women need to be louder about their health concerns, and healthcare professionals need to be better listeners. Timing is critical in heart attacks. The faster treatment begins, the better the outcome. But as Dr. Krishan points out, being heard is just as lifesaving.

The Gender Gap in Heart Health Awareness

The real danger, according to Dr. Krishan, is that public awareness has lagged far behind the reality. Breast cancer campaigns dominate health conversations about women, but heart disease is statistically the bigger threat. Yet because women’s heart attack symptoms are less evident than chest-clutching pain, they are often overlooked.

This creates a vicious cycle. Women do not recognise the symptoms or delay seeking care, and by the time they arrive at the hospital, valuable minutes, or hours, have been lost. On the flip side, doctors themselves may not immediately think “heart attack” if the patient does not fit the classic picture.

Listening to Your Body

Dr. Krishan says listen to your body, trust your instincts, and never dismiss unusual symptoms. If something feels off, whether it is crushing fatigue, unexplained nausea, or dizziness out of nowhere, do not brush it aside.

“Timing saves lives,” she stresses. “But so does being heard.”

Lights will guide you home, but will it treat your mental illness? It could. According to new findings, changing the color of light could help treat mental illness. A psychiatric unit in Trondheim, Norway is testing how light could be used as a potential treatment for mental health conditions like psychosis and depression. The approach is simple, yet innovative that aims on changing the ward's design to help patients in their recovery. As night falls, filters are lowered over windows and lights are changed. This creates a soothing ambiance and eliminates the blue wavelengths that could disrupt body's internal clock.

The findings have been published in PLOS Medicine, that looked on the patients who were treated in the circadian-adapted ward. The study showed that these patients showed greater clinical improvement and less aggressive behavior. "Just by changing the light spectrum, we can improve the quality of treatment," said Havard Kallestad, a researcher at St Olavs hospital who led the study.

Has This Approach Been Used In Other Areas Of Healthcare?

Researchers are now looking at its use for other healthcare areas, which means beyond the psychiatric wards. The UK's National Institute of Health and Care Research (NIHR) has also called for trials to see if this could "reset" the internal clocks of people who are living in care homes to reduce their behavioral disturbances, especially in dementia patients.

Professor Anthony Gordon of the NIHR said that it was about determining if light therapy could be used to reduce anxiety and improve sleep.

Read: Doctor Explains How Sleep Debt Is Becoming A Crisis In Urban Professionals

How Was The Study Conducted?

The psychiatric unit was divided in two identical halves with the same layout, staffing, and facilities. The key difference between the two was the evening light environment. One of the wards used blue-depleted lighting from 6pm onwards, where blinds and filters blocked similar light from windows and screens.

Whereas the other ward used standard hospital lighting and the unique design allowed researchers to study the impact of different lighting on patient recovery.

What Is Circadian Rhythm And How It Impacts Health?

Circadian rhythm is the body's internal 24-hour clock that regulated the sleep-wake cycle, hormones, digestion, and temperature, which aligns them with day and light. It is primarily controlled by light-sensitive brain cells, or what people commonly call the 'body clock'.

Disruption in the cycle could link to various health issues, which includes mental health problems like depression and cardiovascular diseases. This is why the test in Trondheim could prove beneficial in treating patients across the spectrum of illness.

Dialysis patients who took daily fish oil supplements had a 43 percent lower risk of major cardiovascular events, according to a large international clinical trial jointly led in Australia by Monash Health and the School of Clinical Sciences at Monash University.

Published in The New England Journal of Medicine, the study found that participants who took four grams of fish oil each day experienced significantly fewer major cardiovascular events, including heart attack, stroke, cardiac death and vascular-related amputations than those who received a placebo.

The supplement contained the omega-3 fatty acids EPA and DHA, which are naturally found in fish oil.

Adjunct Professor Kevan Polkinghorne, a nephrologist at Monash Health and adjunct in the School of Clinical Sciences, led the Australian portion of the trial said: "Patients on dialysis have extremely high cardiovascular risk, and very few therapies have been shown to reduce that risk," Professor Polkinghorne said. "In a field where many trials have been negative, this is a significant finding.

"Dialysis patients typically have much lower levels of EPA and DHA than the general population. This may help explain the magnitude of benefit observed in this group."

He also noted that results applied specifically to people undergoing haemodialysis for kidney failure and the findings should not be generalized to healthy individuals or to other groups of patients.

What Are Fish Oil Omega-3s?

Omega-3 fatty acids are polyunsaturated fats known for their crucial role in brain function and overall mental health. Fish oil is particularly rich in EPA and DHA, which are vital components of cell membranes and have strong anti-inflammatory effects in the body.

These omega-3s play a critical role in human development, and they are primarily found in fatty fish and fish oil. Since many people do not consume enough fish, supplementation is often recommended to ensure adequate intake of these essential fatty acids.

Although the body can convert another type of omega-3, alpha-linolenic acid (ALA), into EPA and DHA, this process is not highly efficient. As a result, fish oil supplements may provide a convenient way to ensure optimal levels of omega-3s.

Some popular sources of Omega-3 include:

• Salmon
• Cod Liver Oil
• Algae Oil
• Oysters
• Nuts and seeds, such as flaxseeds, chia seeds, and walnuts
• Plant oils, such as flaxseed oil, soybean oil, and canola oil
• Fortified foods, such as eggs, yogurt, juices, milk, etc.

Budget 2026: Cheaper Fish In India

Earlier this month, Finance Minister Nirmala Sitharaman announced a surprising tax reduction for India's fishers and marine industry, and experts say it is good news for you too.

Until now, fish caught by Indian vessels beyond territorial waters and brought back to the country for mass consumption has been treated as import, attracting customs duties and integrated goods and services tax (GST).

The combined tax burden raises costs and compliance issues, which discouraged people from deep-sea and exclusive economic zone (EEZ) fishing as well as

However, during her Union Budget 2026 presentation, Sitharaman proposed that fish caught in the EEZ and high seas by Indian fishing vessels are treated as duty-free when brought into Indian ports and treated as exports when landed at foreign ports.

This means that the market availability for Omega-3 packed fishes including salmon, mackerel, tuna, herring and sardines will significantly increase as their existing steep prices see a tremendous fall.

Malaria infected an estimated 282 million people and caused about 6,10,000 deaths worldwide in 2024, according to the World Health Organization’s (WHO) latest World Malaria Report. The report placed strong emphasis on drug resistance, warning that it remains one of the biggest threats to global elimination goals.

WHO-recommended vaccines helped prevent roughly 170 million cases and one million deaths last year, which is about nine million more than the year before. Around 95 per cent of malaria deaths occurred in the African Region, with children under five forming the largest share.

Within the WHO South-East Asia Region, India represented 73.3 per cent of all malaria cases and 88.7 per cent of all malaria-related deaths. The report also underscored that the world is nowhere close to meeting the targets set under the Global Technical Strategy for malaria 2016–2030.

However, a group of University of Nottingham researchers have now found a key protein that is an enticing target for new antimalarial interventions. The study looked at a protein called Aurora-related kinase 1 (ARK1), which plays an important role in the parasite’s unusual cell division.

ARK1 helps control the parasite’s mitosis (cell division) and organizes a structure called the spindle, which separates genetic material so new parasites can form.

Scientists turned off the ARK1 gene using genetic engineering techniques to see what would happen. Without ARK1, the parasites could not form proper spindles and failed to reproduce, suggesting the protein could be a weak spot that future malaria treatment.

"What makes this discovery so exciting is that the malaria parasite's 'Aurora' complex is very different from the version found in human cells," senior author Rita Tewari said.

What Are Anopheles Stephensi Mosquitoes?

Anopheles stephensi is a malaria-transmitting mosquito originally found in South Asia. Unlike many other malaria vectors, it thrives in cities and breeds in man-made water sources such as storage tanks, containers, and discarded tyres. It can carry both Plasmodium falciparum and P. vivax parasites.

In recent years, this mosquito has spread into several African countries, where it adapts easily and shows resistance to multiple insecticides. This expansion has increased the threat of urban malaria outbreaks, as highlighted by the World Health Organization.

At present, Anopheles stephensi has been detected in nine African countries and is proving difficult to control due to widespread insecticide resistance.

Malaria Vaccines

The report noted that WHO approved the world’s first malaria vaccines in 2021, and 24 countries have now added them to their regular immunisation schedules. Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said that new preventive tools provide reason for optimism, but many obstacles remain.

He pointed out the rise in cases and deaths, the pressure from drug resistance, and the impact of reduced funding. These factors could undermine the progress achieved over the last twenty years.